Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders.

Abstract

Mutations located in the human genes encoding voltage-gated calcium channels are responsible for a variety of diseases referred to as calcium channelopathies, including familial hemiplegic migraine, episodic ataxia type 2, spinocerebellar ataxia type 6, childhood absence epilepsy and autism spectrum disorder, all of which are rare inherited forms of common neurological disorders. The genetic basis of these calcium channelopathies provides a unique opportunity to investigate their underlying mechanisms from the molecular to whole-organism levels. Studies of channelopathies provide insight on the relationships between channel structure and function, and reveal diverse and unexpected physiological roles for the channels. Importantly, these studies may also lead to the identification of drugs for the treatment of genetically acquired channel disorders, as well as to novel therapeutic practices. In this feature review, recent findings regarding neurological calcium channelopathies are discussed.

• Authors: Philippe Lory, Alexandre Mezghrani
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 13 Issue 7 Pg. 467-71 (Jul 2010) ISSN: 2040-3410 [Electronic] England
• PMID: 20582871 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Calcium Channels

Topics

• Animals
• Calcium Channels (genetics)
• Channelopathies (drug therapy, genetics, physiopathology)
• Drug Design
• Drug Evaluation, Preclinical (methods)
• Humans
• Nervous System Diseases (drug therapy, genetics, physiopathology)